Literature DB >> 7591246

Tenascin and fibronectin isoforms in human renal cell carcinomas, renal cell carcinoma cell lines and xenografts in nude mice.

J Lohi1, T Tani, L Laitinen, L Kangas, V P Lehto, I Virtanen.   

Abstract

We studied the expression of tenascin (Tn) and isoforms of fibronectin (Fn) in human renal cell carcinomas (RCC) and oncocytomas, in RCC cell lines and in their s.c. implanted xenografts in nude mice. In well-differentiated RCCs and oncocytomas extra-domain A (EDA)-Fn and Tn immunoreactivities were confined to the basement membranes and blood vessels, while in less-differentiated RCCs they were also widely seen in the stroma, correlating with the morphological differentiation of the tumor. Expression of EDB-Fn and oncofetal (onc)-Fn was very scarce in most of the RCCs and oncocytomas. Western blotting results demonstrated the predominance of the M(r) 190,000 Tn subunit in most RCCs. Among the 4 RCC cell lines, 3 showed Tn in the extracellular matrix. As xenografts, they formed moderately or poorly differentiated tumors, with abundant Tn. Three of the RCC cell lines also showed secretion of EDA-Fn and 2 of them secretion of onc-Fn and EDB-Fn into the culture medium, while in xenografts there was a strong expression of all Fn isoforms. In xenografts, the expression of Tn closely recapitulated that seen in clinical tumors and in the cell lines in vitro, while the expression of Fn isoforms in cultured cells and their xenografts was highly discordant.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591246     DOI: 10.1002/ijc.2910630324

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.

Authors:  Alexander Berndt; Katharina Anger; Petra Richter; Laura Borsi; Simon Brack; Michela Silacci; Marcus Franz; Heiko Wunderlich; Mieczyslaw Gajda; Luciano Zardi; Dario Neri; Hartwig Kosmehl
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

2.  Splicing factors differentially expressed in psoriasis alter mRNA maturation of disease-associated EDA+ fibronectin.

Authors:  E Szlavicz; K Szabo; G Groma; Z Bata-Csorgo; F Pagani; L Kemeny; M Szell
Journal:  Mol Cell Biochem       Date:  2017-06-06       Impact factor: 3.396

Review 3.  Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects.

Authors:  H Kosmehl; A Berndt; D Katenkamp
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

4.  Pathway signature and cellular differentiation in clear cell renal cell carcinoma.

Authors:  Han W Tun; Laura A Marlow; Christina A von Roemeling; Simon J Cooper; Pamela Kreinest; Kevin Wu; Bruce A Luxon; Mala Sinha; Panos Z Anastasiadis; John A Copland
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

5.  Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis.

Authors:  Sophie Astrof; Denise Crowley; Elizabeth L George; Tomohiko Fukuda; Kiyotoshi Sekiguchi; Douglas Hanahan; Richard O Hynes
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

Review 6.  Fibronectins in vascular morphogenesis.

Authors:  Sophie Astrof; Richard O Hynes
Journal:  Angiogenesis       Date:  2009-02-14       Impact factor: 9.596

7.  Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA.

Authors:  C Haglund; S Ylätupa; P Mertaniemi; P Partanen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 8.  Tenascin-C: Form versus function.

Authors:  Sean P Giblin; Kim S Midwood
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

9.  The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma.

Authors:  Daniel Weissinger; Katrin E Tagscherer; Stephan Macher-Göppinger; Axel Haferkamp; Nina Wagener; Wilfried Roth
Journal:  Mol Cancer       Date:  2013-10-10       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.